Eisai Co., Ltd.: all 644 studies

Page 1 of 7. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• A Postmarketing Study of LEQEMBI in Participants With Alzheimer's DiseaseNot yet recruitingNCT07864623
• A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's DiseaseRecruitingNCT07821658
• A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)Not yet recruitingNCT07781345
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)Not yet recruitingNCT07768592Phase 1
• A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy ParticipantsRecruitingNCT07766369Phase 1
• A Post Authorization Registry Study of Participants Treated With LEQEMBIRecruitingNCT07762092
• A Study of E6742 in Participants With Systemic Lupus ErythematosusRecruitingNCT07515014Phase 2
• A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyRecruitingNCT07493265Phase 2
• A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's DiseaseRecruitingNCT06810960
• A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyRecruitingNCT06793709
• A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic SeizuresRecruitingNCT06657378
• A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With LecanemabRecruitingNCT06322667
• A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean ParticipantsRecruitingNCT06246123
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
• Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsRecruitingNCT04271488Phase 1
• An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303AvailableNCT03778424
• A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia DisorderCompletedNCT05594589Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedNCT05312632Phase 4Results posted
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results posted
• A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutCompletedNCT05007392Phase 3Results posted
• A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseCompletedNCT04971733Phase 1/2Results posted
• A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid CopathologyCompletedNCT04764669Phase 2Results posted
• A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT04647383Phase 1Results posted
• A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeTerminatedNCT04572243Phase 3Results posted
• A Study of Lemborexant in Chinese Participants With Insomnia DisorderCompletedNCT04549168Phase 3Results posted
• A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerActive, not recruitingNCT04288089Phase 1Results posted
• A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory OsteosarcomaCompletedNCT04154189Phase 2Results posted
• Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101TerminatedNCT04144140Phase 1Results posted
• A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of InsomniaCompletedNCT04009577Phase 3Results posted
• A Study of Intravenous Perampanel in Japanese Participants With EpilepsyCompletedNCT03754582Phase 2Results posted
• A Study of E6011 in Participants With Active Crohn's DiseaseCompletedNCT03733314Phase 2Results posted
• A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive EpilepsyTerminatedNCT03686033Phase 2Results posted
• A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive EpilepsyTerminatedNCT03603639Phase 2Results posted
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted
• Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib TrialsCompletedNCT03477175Phase 2Results posted
• Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep ApneaCompletedNCT03471871Phase 1Results posted
• Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy BodiesCompletedNCT03467152Phase 2Results posted
• Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationCompletedNCT03456726Phase 2Results posted
• A Study of E7130 in Participants With Solid TumorsTerminatedNCT03444701Phase 1Results posted
• Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal ImpairmentCompletedNCT03443063Phase 1Results posted
• Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)CompletedNCT03441360Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy SubjectsCompletedNCT03440424Phase 1Results posted
• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 YearsTerminatedNCT03338296Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic SeizuresCompletedNCT03288129Phase 4Results posted
• Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerCompletedNCT03250676Phase 1/2Results posted
• Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid TumorsCompletedNCT03245450Phase 1/2Results posted
• Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsCompletedNCT03245151Phase 1/2Results posted
• Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)CompletedNCT03201900Phase 3Results posted
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
• A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT03009344Phase 1Results posted
• A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results posted
• Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results posted
• Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease DementiaCompletedNCT03001557Phase 2Results posted
• A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to BiologicsCompletedNCT02960490Phase 2Results posted
• A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to MethotrexateCompletedNCT02960438Phase 2Results posted
• A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseTerminatedNCT02956486Phase 3Results posted
• Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)CompletedNCT02952820Phase 3Results posted
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
• Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With EpilepsyCompletedNCT02914314Phase 2Results posted
• Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic SeizuresCompletedNCT02849626Phase 3Results posted
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut SyndromeTerminatedNCT02834793Phase 3Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results posted
• Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy VolunteersCompletedNCT02792829Phase 1Results posted
• Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)CompletedNCT02783729Phase 3Results posted
• Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)TerminatedNCT02753595Phase 1/2Results posted
• Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary GeneralizationCompletedNCT02726074Phase 4Results posted
• Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy VolunteersCompletedNCT02723630Phase 1Results posted
• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileCompletedNCT02702388Phase 2Results posted
• Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsCompletedNCT02686164Phase 1Results posted
• Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
• A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseCompletedNCT02660983Phase 4Results posted
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)TerminatedNCT02657369Phase 2Results posted
• Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination ChemotherapyCompletedNCT02579616Phase 2Results posted
• A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results posted
• Study of E7046 in Subjects With Selected Advanced MalignanciesTerminatedNCT02540291Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerCompletedNCT02481050Phase 2Results posted
• Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results posted
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results posted
• An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy SubjectsCompletedNCT02427607Phase 3Results posted
• Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)TerminatedNCT02357147Phase 2Results posted
• Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia DisorderCompletedNCT02350309Phase 1Results posted
• Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's DiseaseTerminatedNCT02322021Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerCompletedNCT02289950Phase 2Results posted
• Phase 1 Study of E7090 in Subjects With Solid TumorCompletedNCT02275910Phase 1Results posted
• Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.CompletedNCT02268812Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and ThrombocytopeniaCompletedNCT02227693Phase 2Results posted
• A Study of E6011 in Japanese Subjects With Rheumatoid ArthritisCompletedNCT02196558Phase 1/2Results posted
• This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including LymphomasCompletedNCT02171260Phase 1Results posted
• A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease PatientsCompletedNCT02135107Phase 3Results posted
• Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT02097056Phase 4Results posted
• A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's DiseaseCompletedNCT02039063Phase 1/2Results posted
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsCompletedNCT02019264Phase 4Results posted
• A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic InsomniaCompletedNCT01995838Phase 2Results posted
• A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese AdultsCompletedNCT01987427Phase 4Results posted
• Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedureCompletedNCT01976104Phase 3Results posted

← Eisai Co., Ltd. overview and focus areas